VCYT Q1 2019 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$30M+47.3% YoY

Gross Profit

$21M71.2% margin

Operating Income

-$2M-7.0% margin

Net Income

-$2M-6.5% margin

EPS (Diluted)

$-0.05

QoQ Revenue Growth

+14.7%

Cash Flow

Operating Cash Flow

-$1M

Free Cash Flow

-$2M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$124M

Total Liabilities

$40M

Stockholders' Equity

$84M

Cash & Equivalents

$68M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$30M	$20M	+47.3%
Gross Profit	$21M	$12M	+72.6%
Operating Income	-$2M	-$9M	+76.9%
Net Income	-$2M	-$9M	+79.1%

Revenue Segments

Provision of Data

$4M84%

Diagnostic Services

$400,0009%

Service

$250,0006%

Product

$90,0002%